After grabbing 46293.0 shares, the institutional investor is now in possession of 46293.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.35% having worth around $9814.0. Moreover, Two Sigma Securities LLC increased its share by 14438.0 to have a control over 14438.0 shares. And Tower Research Capital LLC raised its holdings to 1247.0 shares by acquiring 6876.0 shares or 0.05% of the stake.
Avenue Therapeutics Inc (ATXI) concluded trading on 01/04/24 at a closing price of $0.34, with 181.62 million shares of worth about $61.75 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -69.97% during that period and on Thursday the price saw a gain of about 95.71%. Currently the company’s common shares owned by public are about 13.25M shares, out of which, 9.71M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 3 times over the past 12 months. They bought 819,504 shares in 3 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Series Total Market Inde are the top 3 mutual funds which are holding stakes in Avenue Therapeutics Inc Vanguard Extended Market Index Fu is currently holding 46293.0 shares of worth totaling $9814.0. The company recently came buying 0.0 shares which brought its stake up to 0.35% of the company’s outstanding shares. Fidelity Series Total Market Inde, after buying 6236.0 shares, have now control over 0.05% of the stake in the company. It holds 0.0 shares of worth $1322.0.
Avenue Therapeutics Inc (NASDAQ: ATXI) started trading at $0.285, above $0.11 from concluding price of the previous day. Stock saw a price change of 110.13% in past 5 days and over the past one month there was a price change of 86.54%. Year-to-date (YTD), ATXI shares are showing a performance of 112.61% which decreased to -70.74% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $2.35 during that period. The average intraday trading volume for Avenue Therapeutics Inc shares is 2.18 million. The stock is currently trading 121.75% above its 20-day simple moving average (SMA20), while that difference is up 60.70% for SMA50 and it goes to -56.74% lower than SMA200.
The Vanguard Group, Inc. acquired 46293.0 shares of Avenue Therapeutics Inc having value of about $9814.0. Avenue Therapeutics Inc (NASDAQ: ATXI) currently have 13.25M outstanding shares and institutions hold larger chunk of about 8.57% of that. Holding of mutual funds in the company is about 0.93% while other institutional holders and individual stake holders have control over 10.55% and 0.75% of the stake respectively.
The stock has a current market capitalization of $4.54M and its 3Y-monthly beta is at -0.29. It has posted earnings per share of -$1.40 in the same period. It has Quick Ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ATXI, volatility over the week remained 17.07% while standing at 13.15% over the month.
Analysts are in expectations that Avenue Therapeutics Inc (ATXI) stock would likely to be making an EPS of -$0.1 in the current quarter, while forecast for next quarter EPS is -$0.12 and it is -$0.41 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.11 which is -$0.09 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.75 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 40.18% while it is estimated to increase by 57.95% in next year.
Analysts at 2 brokerage firms have issued recommendations for the Avenue Therapeutics Inc (ATXI)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
